GE Healthcare and Intel Expand Intel Health Guide Marketing Agreement to United Kingdom

GE HealthcareGE Healthcare, a unit of GE (NYSE:GE), and Intel Corporation (NASDAQ: INTC) have expanded their sales and marketing agreement for the Intel Health Guide to include the United Kingdom. GE Healthcare already markets the Intel Health Guide in the United States.

The Intel Health Guide is a care management tool designed for health care professionals who manage patients with chronic conditions such as diabetes, hypertension, chronic obstructive pulmonary disease and heart failure. GE Healthcare's capabilities in disease management, and its distribution reach in the healthcare sector in the UK will help drive understanding of the benefits of this innovative technology, which includes patients' self-monitoring of health status and a direct communications channel to healthcare professionals.

This announcement further expands GE Healthcare's Home Health business in the United Kingdom. Currently the company operates a successful home health business in the United States, providing technologies to help seniors live independently and patients with chronic diseases manage their conditions from their home. With 3,000 employees in the United Kingdom, GE Healthcare is a world class provider of technologies for patient monitoring and diagnosis of disease, and has provided services to the NHS and the U.K. private health sector for more than 30 years. GE Healthcare's Home Health business in the United Kingdom will be managed by Richard Rees-Davies.

The U.K. Department of Health estimates that in Great Britain up to 17.5 million adults and up to three-quarters of those over the age of 75 could be living with a chronic disease. By 2030, the department also estimates that the incidence of chronic disease in those over the age of 65 will more than double,(1) creating an enormous and increasing burden for society. With the dramatic increase of people with chronic conditions and an aging population, there is a need to extend care from the hospital to the home.

Both GE and Intel are currently active in patient monitoring and home health, with well-recognized brands and strong sector expertise:

  • GE QuietCareÒ is a remote passive activity and behavioural monitoring system for the elderly, alerting caregivers to changes that may signal potential health issues or emergency situations such as a fall or emerging health problem. It is used primarily in assisted living facilities across the United States. GE Healthcare also brings significant capabilities in the development of products for critical care patient monitoring, cardiac diagnostics, home respiratory care, and healthcare IT such as electronic medical records and clinical decisions support.
  • The IntelÒ Health Guide is a comprehensive personal health system combining an in-home patient device with an online interface to allow clinicians to monitor patients in their homes and manage care remotely. The Health Guide includes vital sign collection, patient reminders and communications tools such as video conferencing and alerts. Intel already has a number of pilot programs underway in the United Kingdom to assess how the Health Guide can improve care management models in the home.

"Both the Department of Health and the National Health Service are leading some very progressive policy development and pilot programs in this area, and we hope that our Home Health business and expanded agreement with Intel into the U.K. will contribute to that," said Agnes Berzsenyi, general manager of GE Healthcare's Home Health business. "The increasing cost and burden of chronic disease is a huge problem, but we believe new health technologies and new approaches to care will make a difference in the future. It's a perfect fit with GE's healthymagination initiative, which aims to develop innovations that improve access, increase quality and reduce the cost of healthcare."

Intel Digital Health Group's director of sales and marketing Mariah Scott said, "We believe that shifting non-urgent care from the hospital to the home through technologies such as the Intel Health Guide is central to achieving a more personalized and cost-effective health care system. Intel has been working with PCTs, Health Trusts, carer organizations and policy makers in the United Kingdom to support the adoption of innovation in U.K. healthcare delivery and on a number of telehealth pilot schemes. The collaboration with GE Healthcare in the United Kingdom will bring improved understanding of this type of technology to a wider audience and increase the rate of adoption for telehealth systems as a method to help address chronic care challenges and bring benefits to patients and the NHS."

Related news articles:

1. Improving chronic disease management, Department of Health, 2004.

About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com/quietcare

More information about the GE Healthcare and Intel Healthcare Alliance is available at www.ge.com/press/healthalliance.

About Intel
Intel (NASDAQ: INTC), the world leader in silicon innovation, develops technologies, products and initiatives to continually advance how people work and live. Additional information about Intel is available at www.intel.com/pressroom and blogs.intel.com. More information on Intel's Health Guide is available at www.intel.com/go/healthguide.

Intel is a trademark of Intel Corporation or its subsidiaries in the United States and other countries.

Most Popular Now

Open Call HORIZON-JU-IHI-2022-03-05: Dig…

Mental health disorders represent an area of severe unmet public health need. This has been further negatively impacted by the COVID-19 pandemic, with a substantial increase in the number and...

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Brain Area Necessary for Fluid Intellige…

A team led by UCL and UCLH researchers have mapped the parts of the brain that support our ability to solve problems without prior experience - otherwise known as fluid...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...